Wedbush analyst Liana Moussatos reiterated a Buy rating on Aimmune Therapeutics (AIMT – Research Report) today and set a price target of $74.00. The company’s shares closed last Monday at $25.65. According to TipRanks.com, Moussatos ‘ ranking currently consits of